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Case report
The hypereosinophilic syndrome (HES) is a group of dis-
eases characterized by persistent and marked blood eosi-
nophilia, with end-organ involvement and no recognized
secondary cause.
We present a 15 year-old girl who was admitted to our
Department in January 2008 with a four-week history of
headache, arthralgias, myalgias, sore troath and
angioedema. Laboratory test revealed significant leucocy-
tosis (76 × 10ex9/L with 88% eosinophils), thrombocyto-
sis (758 × 10ex9/L), elevated ESR (82 mm/h) and IgE
348.3 (n.v. < 114 g/L), and hypergamaglobulinemia.
Extensive allergologic, immunologic, infectious, and toxi-
cological studies were negative. Bone marrow biopsy
showed increased cellularity with increased granulopoie-
sis predominated by cells of the eosinophilic lineage, with
a normal karyotype. Patient was negative for the FIP1L1-
PDGFRA fusion kinase and BCR-ABL gene fusion by RT-
PCR: Abdomen CT showed diffuse small intestine wall
thickness, and cardiac echocardiogram showed thickness
of the left ventricular wall and interventricular septum.
The biopsy of myocardium and small intestine was
planned, but in a mean time patient's condition was wors-
ened. She developed hypoproteinemia (46 g/L), general-
ised oedema, and diarrhoea. A diagnosis of idiopathic
HES was made and methylprednisolone was introduced
in the therapy. She had rapid response to methylpred-
nisolone (within 12 hours), with normalisation of the
blood counts, protein level and regression of oedema.
Methylprednisolone was slowly tapered, and at present,
HES is in complete clinical and laboratory remission.
Conclusion
Although HES is extremely rare in childhood, it has to be
considered, when a patient is presented with significant
leucocytosis and eosinophilia.
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